The global generic oncology sterile injectable market is expected to grow at a significant CAGR during the forecast period. Generic oncology sterile injectables are biologics that have the same active ingredients as the branded version, however, differ solely in the inactive elements. These sterile oncology injectables are used to treat a wide range of cancers, including breast, prostate, colorectal, melanoma, lung, and bronchus cancers. The injectables are commonly used as they are less expensive than branded medications.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/generic-oncology-sterile-injectable-market
Further, manufacturers present in the US are concentrating on releasing new products to provide low-cost therapy to patients which are driving the market. Moreover, Owing to the increasing number of product launches in the US, North America is anticipated to hold a dominating position in the global generic oncology sterile injectable market. For instance, in September 2019, Mylan N.V. announced Fulvestrant Injection, a generic version of AstraZeneca’s Faslodex Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe for the treatment of advanced breast cancer in the US. Asia-Pacific is expected to be the fastest-growing region in the market owing to increased measures taken by key players to expand the presence of their injectables in this region.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Eli Lilly & Co., Mylan N.V., Sandoz International GmbH, and Teva Pharmaceutical Industries Ltd., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Generic Oncology Sterile Injectable Market by Segment
By Product Type
- Chemotherapy
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
By Disease Indication
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
A full report of Generic Oncology Sterile Injectable Market is available at: https://www.omrglobal.com/industry-reports/generic-oncology-sterile-injectable-market
Generic Oncology Sterile Injectable Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Eli Lilly & Co.
- Mylan N.V.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
